Possible $4M Price for AVXS-101, ‘Foundational’ SMA Gene Therapy, Could Be Cost-Effective, Novartis Says
Novartis may put a $4 million to $5 million price tag on its “one-time, potentially curative” gene therapy AVXS-101 for spinal muscular atrophy (SMA) and believes this could be cost-effective. “Four million dollars is a significant amount of money, but we believe that this is a cost-effective point,”…